A new weight-loss jab will be rolled out on the NHS in England - but it could take 12 years for everyone to receive it, the ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

A new study is shedding light on which of two drugs currently approved by the U.S. Food and Drug Administration for weight ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

Analysts see the market for GLP-1 weight loss treatments rising to around $70 billion over the next five years.

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

It comes as a trial by Mounjaro manufacturer Eli Lilly – known as Surmount-5 – found patients on tirzepatide recorded a ...

A drug dubbed the “King Kong of weight loss jabs” will start being given to the most dangerously obese in the New Year. However the NHS spending watchdog has announced Mounjaro will only be given to ...

Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...

The “difficult decision” was made “in order to protect other vital NHS services”, the National Institute for Health and Care ...

Pharmaceutical giants Eli Lilly and Company & Novo Nordisk A/S face challenges in the obesity market despite promising data.

SURMOUNT-5’s results reflect those of multiple real-world studies, which have found that tirzepatide treatment results in ...